24
Participants
Start Date
May 8, 2024
Primary Completion Date
October 31, 2025
Study Completion Date
July 31, 2028
Danvatirsen
Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).
Danvatirsen + Venetoclax
"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
M.D. Anderson Cancer Center, Department of Leukemia, Houston
Collaborators (1)
M.D. Anderson Cancer Center
OTHER
Flamingo Therapeutics NV
INDUSTRY
Montefiore Medical Center
OTHER